Sort   by:  
 Page size 
ProteomicsHuman whole plasma RFU quantitative proteomics for pre-post meditation retreat
SomaLogic platform was used to identify and quantify protein levels in whole plasma from 20 individual human meditation retreat attendees before and after a 1-week mind-body intervention (Kundalini meditation, reconceptualization, and open label placebo healing ritual).
ORGANISM(S): Homo sapiens (Human) 
2025-11-17 | PAD000010 | Pride
Meditation Plasma Human Somalogic 
UnknownSomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
Not available
S-EPMC11269579 | biostudies-literature
ProteomicsMulti-omics identify LRRC15 as a COVID-19 severity predictor and persistent pro-thrombotic signals in convalescence
We performed longitudinal blood sampling of end-stage kidney disease (ESKD) patients with COVID-19, collecting samples pre-infection and serially during infection. SomaLogic proteomics data were generated for two cohorts. The Wave 1 cohort consists of samples collected from ESKD patients during the ...
ORGANISM(S): Homo sapiens (Human) 
2025-03-17 | PAD000003 | Pride
Affinity proteomics Somascan 
UnknownElucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
Not available
S-EPMC3630118 | biostudies-literature
ProteomicsThe effect of preanalytical factors on cerebrospinal fluid and plasma proteomics
This dataset contains SOMAscan proteomic data obtained from human cerebrospinal fluid (CSF) and plasma samples to evaluate the impact of pre-analytical variables (PAVs) on proteomic stability. The study systematically assessed common processing factors such as storage temperature, time-to-processing...
ORGANISM(S): Homo sapiens (Human) 
2026-09-07 | PAD000011 | Pride
Cerebrospinal fluid (csf) Somascan Pre-analytical variables (pavs) Biobanking 
GenomicsProteomics dat
SomaLogic data
EGAD00010002447 | EGA
ProteomicsSomaScan of Plasma from Psilocybin-Treated Human Participants
Analysis of plasma from two human participants treated with 25 mg oral psilocybin capsules. Blood was collected at baseline, 1 hour, and 2.5 hours after treatment.
ORGANISM(S): Homo sapiens (Human) 
2026-09-08 | PAD000051 | Pride
Human Psilocybin Plasma Somascan 
UnknownPlatform-dependent effects of genetic variants on plasma APOL1.
Not available
S-EPMC11838367 | biostudies-literature
UnknownModified nucleotides may have enhanced early RNA catalysis.
Not available
S-EPMC7165471 | biostudies-literature
UnknownDiscovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.
Not available
S-EPMC5625392 | biostudies-literature
Sort   by:  
 Page size